Trial of Thrombectomy for Stroke with a Large Infarct of Unrestricted Size

Vincent Costalat(Inserm), Tudor G. Jovin(Inserm), Jean François Albucher(Inserm), Christophe Cognard(Inserm), Hilde Hénon(Inserm), Nasreddine Nouri(Inserm), Benjamin Gory(Inserm), Sébastien Richard(Inserm), Gaultier Marnat(Inserm), Igor Sibon(Inserm), Federico Di Maria(Inserm), Mariam Annan(Inserm), Grégoire Boulouis(Inserm), Pere Cardona(Inserm), Michaël Obadia(Inserm), Michel Piotin(Inserm), Romain Bourcier(Inserm), Benoît Guillon(Inserm), Sophie Godard(Inserm), A. Pasco-Papon(Inserm), Omer Eker(Inserm), Tae‐Hee Cho(Inserm), Guillaume Turc(Inserm), Olivier Naggara(Inserm), Stéphane Velasco(Inserm), M Lamy(Inserm), Frédéric Clarençon(Inserm), Sonia Alamowitch(Inserm), Arturo Renú(Inserm), Laurent Suissa(Inserm), Hervé Brunel(Inserm), Jean‐Christophe Gentric(Inserm), Serge Timsit(Inserm), Chantal Lamy(Inserm), Cyril Chivot(Inserm), Francisco Macian-Montoro(Inserm), Charbel Mounayer(Inserm), Ozlem Ozkul-Wermester(Inserm), Chrysanthi Papagiannaki(Inserm), Valérie Wolff(Inserm), Raoul Pop(Inserm), Anna Ferrier(Inserm), Emmanuel Chabert(Inserm), F. Ricolfi(Inserm), Yannick Béjot(Inserm), Elena López‐Cancio(Inserm), Pedro Vega(Inserm), Laurent Spelle(Inserm), Christian Denier(Inserm), Mónica Millán(Inserm), Juan F. Arenillas(Inserm), Mikaël Mazighi(Inserm), Emmanuel Houdart(Inserm), Maria del Mar Freijo(Inserm), Alain Duhamel(Inserm), Nerses Sanossian(Inserm), David S. Liebeskind(Inserm), Julien Labreuche(Inserm), Bertrand Lapergue(Inserm), Caroline Arquizan(Inserm)
New England Journal of Medicine
May 8, 2024
Cited by 249

Abstract

BACKGROUND: The use of thrombectomy in patients with acute stroke and a large infarct of unrestricted size has not been well studied. METHODS: We assigned, in a 1:1 ratio, patients with proximal cerebral vessel occlusion in the anterior circulation and a large infarct (as defined by an Alberta Stroke Program Early Computed Tomographic Score of ≤5; values range from 0 to 10) detected on magnetic resonance imaging or computed tomography within 6.5 hours after symptom onset to undergo endovascular thrombectomy and receive medical care (thrombectomy group) or to receive medical care alone (control group). The primary outcome was the score on the modified Rankin scale at 90 days (scores range from 0 to 6, with higher scores indicating greater disability). The primary safety outcome was death from any cause at 90 days, and an ancillary safety outcome was symptomatic intracerebral hemorrhage. RESULTS: A total of 333 patients were assigned to either the thrombectomy group (166 patients) or the control group (167 patients); 9 were excluded from the analysis because of consent withdrawal or legal reasons. The trial was stopped early because results of similar trials favored thrombectomy. Approximately 35% of the patients received thrombolysis therapy. The median modified Rankin scale score at 90 days was 4 in the thrombectomy group and 6 in the control group (generalized odds ratio, 1.63; 95% confidence interval [CI], 1.29 to 2.06; P<0.001). Death from any cause at 90 days occurred in 36.1% of the patients in the thrombectomy group and in 55.5% of those in the control group (adjusted relative risk, 0.65; 95% CI, 0.50 to 0.84), and the percentage of patients with symptomatic intracerebral hemorrhage was 9.6% and 5.7%, respectively (adjusted relative risk, 1.73; 95% CI, 0.78 to 4.68). Eleven procedure-related complications occurred in the thrombectomy group. CONCLUSIONS: In patients with acute stroke and a large infarct of unrestricted size, thrombectomy plus medical care resulted in better functional outcomes and lower mortality than medical care alone but led to a higher incidence of symptomatic intracerebral hemorrhage. (Funded by Montpellier University Hospital; LASTE ClinicalTrials.gov number, NCT03811769.).


Related Papers

No related papers found

Powered by citation graph analysis